Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly

Ales Janda, Petr Sedlacek, Manfred Hönig, Wilhelm Friedrich, Martin Champagne, Tadashi Matsumoto, Alain Fischer, Benedicte Neven, Audrey Contet, Danielle Bensoussan, Pierre Bordigoni, David M. Loeb, William Savage, Nada Jabado, Francisco A. Bonilla, Mary A. Slatter, E. Graham Davies, Andrew R. Gennery

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41%, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/ mm3, respectively, CD4 +/CD45RA+ cells remained very low, whereas mitogen responses were normalized.

Original languageEnglish (US)
Pages (from-to)2229-2236
Number of pages8
JournalBlood
Volume116
Issue number13
DOIs
StatePublished - Sep 30 2010
Externally publishedYes

Fingerprint

DiGeorge Syndrome
Cell Transplantation
HLA Antigens
T-cells
Blood
Siblings
Unrelated Donors
Mitogens
Grafts
Transplantation
Bone
T-Lymphocytes
Graft vs Host Disease
CD4 Lymphocyte Count
Surveys and Questionnaires
Fetal Blood
Survivors
Survival Rate
Bone Marrow
Survival

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Janda, A., Sedlacek, P., Hönig, M., Friedrich, W., Champagne, M., Matsumoto, T., ... Gennery, A. R. (2010). Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. Blood, 116(13), 2229-2236. https://doi.org/10.1182/blood-2010-03-275966

Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. / Janda, Ales; Sedlacek, Petr; Hönig, Manfred; Friedrich, Wilhelm; Champagne, Martin; Matsumoto, Tadashi; Fischer, Alain; Neven, Benedicte; Contet, Audrey; Bensoussan, Danielle; Bordigoni, Pierre; Loeb, David M.; Savage, William; Jabado, Nada; Bonilla, Francisco A.; Slatter, Mary A.; Davies, E. Graham; Gennery, Andrew R.

In: Blood, Vol. 116, No. 13, 30.09.2010, p. 2229-2236.

Research output: Contribution to journalArticle

Janda, A, Sedlacek, P, Hönig, M, Friedrich, W, Champagne, M, Matsumoto, T, Fischer, A, Neven, B, Contet, A, Bensoussan, D, Bordigoni, P, Loeb, DM, Savage, W, Jabado, N, Bonilla, FA, Slatter, MA, Davies, EG & Gennery, AR 2010, 'Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly', Blood, vol. 116, no. 13, pp. 2229-2236. https://doi.org/10.1182/blood-2010-03-275966
Janda, Ales ; Sedlacek, Petr ; Hönig, Manfred ; Friedrich, Wilhelm ; Champagne, Martin ; Matsumoto, Tadashi ; Fischer, Alain ; Neven, Benedicte ; Contet, Audrey ; Bensoussan, Danielle ; Bordigoni, Pierre ; Loeb, David M. ; Savage, William ; Jabado, Nada ; Bonilla, Francisco A. ; Slatter, Mary A. ; Davies, E. Graham ; Gennery, Andrew R. / Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. In: Blood. 2010 ; Vol. 116, No. 13. pp. 2229-2236.
@article{3eba77ec3d434925bd8c71b90518150f,
title = "Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly",
abstract = "Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41{\%}, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/ mm3, respectively, CD4 +/CD45RA+ cells remained very low, whereas mitogen responses were normalized.",
author = "Ales Janda and Petr Sedlacek and Manfred H{\"o}nig and Wilhelm Friedrich and Martin Champagne and Tadashi Matsumoto and Alain Fischer and Benedicte Neven and Audrey Contet and Danielle Bensoussan and Pierre Bordigoni and Loeb, {David M.} and William Savage and Nada Jabado and Bonilla, {Francisco A.} and Slatter, {Mary A.} and Davies, {E. Graham} and Gennery, {Andrew R.}",
year = "2010",
month = "9",
day = "30",
doi = "10.1182/blood-2010-03-275966",
language = "English (US)",
volume = "116",
pages = "2229--2236",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly

AU - Janda, Ales

AU - Sedlacek, Petr

AU - Hönig, Manfred

AU - Friedrich, Wilhelm

AU - Champagne, Martin

AU - Matsumoto, Tadashi

AU - Fischer, Alain

AU - Neven, Benedicte

AU - Contet, Audrey

AU - Bensoussan, Danielle

AU - Bordigoni, Pierre

AU - Loeb, David M.

AU - Savage, William

AU - Jabado, Nada

AU - Bonilla, Francisco A.

AU - Slatter, Mary A.

AU - Davies, E. Graham

AU - Gennery, Andrew R.

PY - 2010/9/30

Y1 - 2010/9/30

N2 - Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41%, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/ mm3, respectively, CD4 +/CD45RA+ cells remained very low, whereas mitogen responses were normalized.

AB - Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41%, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/ mm3, respectively, CD4 +/CD45RA+ cells remained very low, whereas mitogen responses were normalized.

UR - http://www.scopus.com/inward/record.url?scp=77957714384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957714384&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-03-275966

DO - 10.1182/blood-2010-03-275966

M3 - Article

VL - 116

SP - 2229

EP - 2236

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -